Molecular targeted therapies for indolent lymphomas: where are we?


https://doi.org/10.4081/hmr.v3i3.554
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 163
PDF: 187
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

During the last decade the development of new drugs for the treatment of hematologic malignancies has become really promising. This innovative drug development is based on the translation into biochemical pharmacology of specific alterations of biological functions affecting tumour cells1. One of the most important examples is imatinib: it showed that it was possible to nullify the pathognomic genetic lesion of chronic myelogenous leukemia (CML). Drugs targeting unique disease-specific pathways have also found potential applicability in treating malignancies such as CD20-positive non-Hodgkin’s lymphoma (rituximab), follicular lymphoma (Bcl-2-targeted agents2-6) and other B-cell neoplasms (splenic tyrosine kinase [Syk] inhibitors;7-9 IkB kinase inhibitors10).

Supporting Agencies


Saglio, G., Parvis, G., & Bosa, M. (2009). Molecular targeted therapies for indolent lymphomas: where are we?. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.554
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC